StreetAlpha.app
Home › Stocks › QURE

uniQure N.V. (QURE)

Healthcare
$20.78
▼ −5.03%
LAST CLOSE · NOV 17

uniQure develops gene therapies for rare and serious diseases, including Huntington's disease and Fabry disease. It last closed at $20.78 on Nov 17, down 5.03% on the day. The average 12-month price target from 4 analysts is $38.75 (+86.5% from the last close), with a high of $48.00 and a low of $28.00. Analyst consensus is Buy, based on the latest ratings from 4 firms (2 buy, 2 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in QURE, 75% of them bullish and 25% bearish.

AI Auto Pilots
Is QURE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$20.2M
+28.0% vs a year ago
Net income
−$232.9M
−1154.8% margin
EPS (diluted)
−$3.51
Free cash flow
−$193.0M
−956.8% margin
Valuation
Market cap
$1.5B
70.1M shares
P/E
–
No P/E while losing money
Price to sales
72.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$98.4M
At Sep 30
Debt
$50.3M
At Sep 30
Shareholder equity
$294.7M
Shares outstanding
70.1M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $524.0M$524.0MFY2021FY2022: $106.5M$106.5MFY2022FY2023: $15.8M$15.8MFY2023FY2024: $27.1M$27.1MFY2024FY2025: $16.1M$16.1MFY2025

From QURE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
4firms
2 Buy2 Hold0 Sell
Each firm's latest rating on QURE in the past 90 days
Average 12-month target
$38.75
▲ 86.5% upside

Based on 4 analysts who set a price target on QURE in the past 90 days. The average target is $38.75, with a high of $48.00 and a low of $28.00, compared with the last close of $20.78.

$18$30$42$53PAST 35 TRADING DAYS12-MONTH TARGETSHIGH $48AVG $38.75LOW $28May 29LAST CLOSE+12 MO$18$30$42$53PAST 35 DAYSTARGETSHIGH $48AVG $38.75LOW $28May 29LAST CLOSE+12 MO
Highest target$48.00
Average target$38.75
Lowest target$28.00
Latest rating changes
UBSAssumed coverage
Oct 15Buy$48
BarclaysDowngrade
Oct 5Hold$60 → $28
RBC CapitalTarget lowered
Oct 2Buy$65 → $48
Goldman SachsTarget lowered
Sep 30Hold$46 → $31
Wells FargoTarget raised
Jul 30Buy$15 → $75
DateFirmActionRatingPrice target
Oct 15UBSAssumed coverageBuy$48
Oct 5BarclaysDowngradeHold$60 → $28
Oct 2RBC CapitalTarget loweredBuy$65 → $48
Sep 30Goldman SachsTarget loweredHold$46 → $31
Jul 30Wells FargoTarget raisedBuy$15 → $75
Loading…

Technical Analysis

QURE · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 11% below its 20 day and 37% below its 50 day average. It is 43% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the swing low (Nov 5) at $20.58, and the nearest resistance the Pivot at $21.04.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 8.8%/day
Key levels
$51.7252 week high+148.9%
$36.46100 day average+75.5%
$29.62200 day average+42.5%
$28.5550 day average+37.4%
$26.19Swing high (Nov 12)+26.0%
$23.1520 day average+11.4%
$21.53Pivot R1+3.6%
$21.04Pivot+1.3%
$20.78Last close
$20.58Swing low (Nov 5)−1.0%
$20.30Pivot S1−2.3%
$8.7352 week low−58.0%
Indicators
RSI (14)36.51Weak, oversold below 30Neutral
MACD-1.37Above its signal lineBullish
Stochastic26.5Middle of its rangeNeutral
ADX (14)23.1Weak trend
Williams %R-96.3Oversold below −80, overbought above −20Oversold
CCI (20)-142.8Oversold below −100, overbought above 100Oversold
Rate of change−12.9%Change over 10 sessionsBearish
ATR (14)$1.82Typical daily range, 8.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for QURE

What happened before

See how QURE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish3 bullish and 1 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow QURE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How QURE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
4
Bullish
3
75%
Bearish
1
25%
Date span
Sep 8 – Nov 10
Loading…

See today’s whale options flow across the market →

QURE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ●136 buying vs 125 selling
  • ▼Held by funds -9.5 pts
  • ▼Funds holding -16
  • ▼Superinvestors: 0 added, 3 cut
  • ▼Put/call 0.20 to 0.37
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding241257−6.2%
In funds' top 1036−50.0%
Held by funds85.6%95.2%−9.5 pts
New / increased44 / 9289 / 87−22.7%
Reduced / sold out67 / 5860 / 50+13.6%
Put/call ratio0.370.20+87.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See QURE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QURE is in one of them and how their past QURE trades turned out.

QURE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered QURE in an article yet. Here's the latest on the wider market.

About uniQure N.V.

uniQure is a gene therapy company based in Amsterdam. It develops treatments meant to be given as a single dose to patients with rare and other serious diseases. Its clinical programs target Huntington's disease, temporal lobe epilepsy, Fabry disease, and a form of amyotrophic lateral sclerosis linked to SOD1 gene mutations. These candidates are still in clinical development and have not yet been approved for sale.

Headquarters
Amsterdam